15,215 Shares in Global X Genomics & Biotechnology ETF (NASDAQ:GNOM) Acquired by Citadel Advisors LLC

Citadel Advisors LLC acquired a new stake in Global X Genomics & Biotechnology ETF (NASDAQ:GNOM) in the 4th quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The fund acquired 15,215 shares of the company’s stock, valued at approximately $148,000. Citadel Advisors LLC owned about 0.22% of Global X Genomics & Biotechnology ETF as of its most recent filing with the Securities & Exchange Commission.

Other institutional investors have also recently made changes to their positions in the company. SBI Securities Co. Ltd. purchased a new position in shares of Global X Genomics & Biotechnology ETF in the fourth quarter worth $50,000. Sanctuary Advisors LLC bought a new stake in Global X Genomics & Biotechnology ETF in the 4th quarter worth $104,000. Sei Investments Co. purchased a new position in shares of Global X Genomics & Biotechnology ETF in the fourth quarter valued at about $114,000. Smartleaf Asset Management LLC raised its stake in shares of Global X Genomics & Biotechnology ETF by 11.2% during the fourth quarter. Smartleaf Asset Management LLC now owns 12,604 shares of the company’s stock valued at $122,000 after acquiring an additional 1,265 shares during the last quarter. Finally, Atria Investments Inc boosted its holdings in shares of Global X Genomics & Biotechnology ETF by 27.8% during the fourth quarter. Atria Investments Inc now owns 13,813 shares of the company’s stock worth $134,000 after purchasing an additional 3,006 shares during the period. Hedge funds and other institutional investors own 56.95% of the company’s stock.

Global X Genomics & Biotechnology ETF Stock Performance

NASDAQ GNOM opened at $8.36 on Monday. The stock has a market cap of $50.66 million, a P/E ratio of -3.57 and a beta of 1.03. Global X Genomics & Biotechnology ETF has a fifty-two week low of $6.80 and a fifty-two week high of $11.88. The stock has a 50 day simple moving average of $7.76 and a two-hundred day simple moving average of $9.04.

Global X Genomics & Biotechnology ETF Profile

Complete Genomics, Inc is a life sciences company that has developed and commercialized a deoxyribonucleic acid (DNA) sequencing platform. Its complete genomics analysis platform (CGA) Platform, combines its human genome sequencing technology with its advanced informatics and data management software and its end-to-end, outsourced service model to provide its customers with data that is ready to be used for genome-based research.